12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD5363: Phase I started

AstraZeneca began an open-label, European Phase I trial to evaluate ascending-doses of oral AZD5363 in about 84 patients. AstraZeneca has worldwide...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >